Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Recruiting · Enrollment 2539
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r | n/r |
| Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r | n/r |
| Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention | n/r | n/r | n/r | n/r | n/r |
| Arm 4: Placebo once weekly + lifestyle intervention | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.